STOCKS TELEGRAPH

Tag: FBIO

  • 3 Stocks Worth Watching Today: Cardiol Therapeutics (CRDL), Fortress Biotech (FBIO), Dogwood Therapeutics (DWTX)

    3 Stocks Worth Watching Today: Cardiol Therapeutics (CRDL), Fortress Biotech (FBIO), Dogwood Therapeutics (DWTX)

    Investor attention in the healthcare sector continues to be shaped by the balance between near-term clinical catalysts and long-term commercial potential. While short-term price action can be influenced by sentiment and liquidity conditions, sustained valuation growth is typically driven by meaningful clinical validation. This dynamic keeps focus firmly on programs advancing through pivotal stages of development.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is entering an increasingly important stage of development as growing scientific validation supports the advancement of its lead cardiovascular therapy. For clinical-stage biotech companies, publication in respected peer-reviewed journals can significantly strengthen credibility with both investors and the broader medical community.

    Market Momentum

    As of May 8, 2026, CRDL closed at $1.32, up 1.54%, with trading volume reaching 578,846 shares compared to an average volume of 686,648 shares. The company currently holds a market capitalization of $147.418M and a beta of 0.43, reflecting relatively moderate volatility for a small-cap biotech stock. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.40 suggests substantial upside potential tied to future clinical milestones.

    Clinical Validation

    Cardiol recently announced that Phase II results for CardiolRx™ in recurrent pericarditis will be published in the Journal of the American Heart Association. The study demonstrated rapid and sustained reductions in pain and inflammation, particularly among patients with more severe disease at baseline. Researchers also observed fewer annual recurrence episodes, alongside favorable safety and tolerability findings.

    Impact on Late-Stage Development

    The Phase II data continues to support the advancement of the ongoing Phase III MAVERIC trial, which has now enrolled more than 75% of participants. Importantly, the earlier findings also helped shape the design of the pivotal study, strengthening the clinical rationale behind CardiolRx™’s development strategy.

    Outlook

    With a peer-reviewed publication adding external validation to its clinical profile, Cardiol appears increasingly well-positioned as it advances toward key regulatory and commercialization milestones.

    Fortress Biotech Inc (FBIO)

    Fortress Biotech Inc (NASDAQ: FBIO) started the day on May 08, 2026, with a price decrease of -0.42% at $2.39. During the day, the stock rose to $2.44 and sank to $2.36. Taking a long-term approach, FBIO posted a 52-week range of $1.60-$4.53.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 62.98%. Meanwhile, its Annual Earnings per share during the time was 62.98%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is -900.00%. This publicly-traded company’s shares outstanding now amount to $31.36 million, simultaneously with a float of $24.35 million. The organization now has a market capitalization of $76.96 million.

    Dogwood Therapeutics Inc (DWTX)

    As of May 08, 2026, Dogwood Therapeutics Inc (NASDAQ: DWTX) got off with the flyer as it spiked 5.77% to $1.65. During the day, the stock rose to $1.66 and sank to $1.55. Taking a long-term approach, DWTX posted a 52-week range of $1.28-$9.50.

    In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was 25.53%. Meanwhile, its Annual Earnings per share during the time was 25.53%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 85.69%. This publicly-traded company’s shares outstanding now amount to $33.40 million, simultaneously with a float of $33.40 million. The organization now has a market capitalization of $55.11 million.

  • Fortess Biotech Inc. (FBIO) soared in the after-market trading session; here’s why

    Fortess Biotech Inc. (FBIO) soared in the after-market trading session; here’s why

    Fortress Biotech Inc. (FBIO) stock was rising by 8.82% to trade at the price of %5.92 in the aftermarket, at the time of writing. FBIO’s stock closed in Friday’s session by trading at $5.44 which is an 11.48% gain. The stock volume traded is 22 million shares which is higher than the average daily volume of 1.63 million for the past 50 days. FBIO shares had moved by 41.30% in the past week and in the past three months It gained 56.77%. Furthermore, for the past 6 months and 12 months, it has added 26.22% and 186.32% respectively.

    Fortress’s operational activities in April

    Fortress Biotech Inc. and specifically its partner Journey Medical Corporation’s stock have been performing fundamentally well recently and they have been very active operation activity-wise in the start of April.

    Fortress BioTech Inc. (NASDAQ: FBIO) announced on 7th April 2021 that it will participate on the 20th Annual Needham Virtual Healthcare Conference which will take place from today 12th to 15th of April. Fortress’s Chief Executive Officer, President, and Chairman, LindsayA. Rosenwald, M.D, will participate in the meeting as well as one-on-one meetings during the conference. The company’s presentation will be available on their website link (click here)

    On 5th April, the partner company of Fortress BiotTech, Inc. named Journey Medical Corporation announced that it has entered into an agreement on Line of Credit with East West Bank for the amount of $7.5 million. This line of credit will be entered and received into receivables and cash of the company with an interest rate greater of 4.25%.

    On 1sth April, the Journey Medical Corporation had announced an agreement to acquire Qbrexza (glycopyrronium) which is the treatment of primary axillary hypherhidrosis in adults and pediatric populations, as well as self-administered patients. This issue is pertinent to the characterization of excessive sweating on the hand’s palms, soles of feet, armpit, groin area and under the breasts. Qbrexza is approved by the Food and Drug Administration and has generated $24 million net sales in the USA, 2020. Journey Medical Corporation will close the transaction early in the second quarter of this year.

    Fortress Biotech Inc.’s candidate programs and acquisitions

    Fortress Biotech Inc. is a biopharmaceutical company that focuses mainly on acquisition, development and commercialization of high-potential marketed and development-stage drugs and drug candidates. The product candidates that Fortress currently has in its pipeline include the bio-pharmaceutical areas of oncology, gene therapy and rare diseases. For these areas of expertise, 7 of the candidates have been marketed as pharmaceutically prescribed products and over 25 programs in development progress. Together these developed and developing products in the pipeline cover 6 large market areas which show that the FBIO stock is highly diversified.

    The business model

    To maintain these diversified and expansionary operational activities, FBIO has a team model structured around world-class business development team that has the expertise of the biopharmaceutical industry. This is highly crucial for the company to expand the company into new avenues of biopharmaceutical product opportunities.

    FBIO stock, as an opportunity to expand biopharmaceutical products, has extended partnerships with several world-renowned and famous biopharmaceutical companies as well as institutions which include AstraZeneca, Fred Hutchinson Cancer Research Center, Nationwide Children’s Hospital as well as many others.